CrossRef Text and Data Mining

Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.

Efficacy of Olaparib in Treatment-Refractory, Metastatic Breast Cancer with Uncommon Somatic BRCA Mutations Detected in Circulating Tumor DNA

Jung-Ki Yoon, Jongseong Ahn, Sheehyun Kim, Hwang-Phil Kim, Jun-kyu Kang, Duhee Bang, Yoojoo Lim, Tae-You Kim

Cancer Research and Treatment. 2023;55(3):1048-1052. Published online 2023 January 31 DOI: https://doi.org/10.4143/crt.2022.1529

Efficacy of Olaparib in Treatment-Refractory, Metastatic Breast Cancer with Uncommon Somatic BRCA Mutations Detected in Circulating Tumor DNA

Jung-Ki Yoon, Jongseong Ahn, Sheehyun Kim, Hwang-Phil Kim, Jun-kyu Kang, Duhee Bang, Yoojoo Lim, Tae-You Kim

Cancer Research and Treatment. 2023;55(3):1048-1052

Link1

Link2 Link3

TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients

Sandra V Fernandez, Catherine Bingham, Patricia Fittipaldi, Laura Austin, Juan Palazzo, Gary Palmer, Katherine Alpaugh, Massimo Cristofanilli

Breast Cancer Research. 2014;16(5):

Link1

Link2 Link3 Link4

Targeted Next-Generation Sequencing of Circulating Tumor DNA Mutations among Metastatic Breast Cancer Patients

Minying Sun, Fangqin Lin, Lujia Chen, Hong Li, Weiquan Lin, Hongyan Du, Xuexi Yang, Ming Li

. 2021;

Link1 Link2

Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use?

C. Montagut, D.W. Tsui, L.A. Diaz

Annals of Oncology. 2018;29(5):1083-1084

Link1 Link2 Link3

PCN95 COST-EFFECTIVENESS ANALYSIS OF GERMLINE BRCA MUTATION TESTING AND OLAPARIB TREATMENT IN METASTATIC BREAST CANCER: AN EVALUATION OF CODEPENDENT TECHNOLOGIES

H. Tuffaha, P. Scuffham

Value in Health. 2019;22:S454

Link1 Link2

Cost-effectiveness analysis of olaparib treatment for metastatic castration-resistant prostate cancer with BRCA 1/2 mutations following a new hormonal agent in China

Poucheok Pang, Baoying Tan, Jianwei Xuan

Intelligent Pharmacy. 2023;1(2):67-72

Link1 Link2

Liquid Biopsy in Metastatic Breast Cancer: Current Role of Circulating Tumor Cells and Circulating Tumor DNA

Maggie Banys-Paluchowski, Tanja N. Fehm, Donata Grimm-Glang, Achim Rody, Natalia Krawczyk

Oncology Research and Treatment. 2021;45(1-2):4-11

Link1 Link2

Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes

Elaine M. Walsh, Neha Mangini, John Fetting, Deborah Armstrong, Isaac S. Chan, Roisin M. Connolly, Katie Fiallos, Jennifer Lehman, Raquel Nunes, Dana Petry, Jeffrey Reynolds, Mirat Shah, Karen L Smith, Kala Visvanathan, Josh Lauring, Ben H Park, Vered Stearns, Antonio C. Wolff

Clinical Breast Cancer. 2022;22(4):319-325

Link1 Link2

Somatic mutations of the HER2 in metastatic breast cancer

Yi Fang, Yanxia Jiang, Xin Wang, Xue Yang, Yinqi Gao, Jing Wang

Tumor Biology. 2014;35(12):11851-11854

Link1

Link2 Link3

Circulating tumor cells, circulating tumor DNA, and disease characteristics in young women with metastatic breast cancer

Ami N. Shah, Kristen J. Carroll, Lorenzo Gerratana, Chenyu Lin, Andrew A. Davis, Qiang Zhang, Saya Jacob, Brian Finkelman, Youbin Zhang, Wenen Qiang, Paolo D’Amico, Carolina Reduzzi, William J. Gradishar, Amir Behdad, Massimo Cristofanilli

Breast Cancer Research and Treatment. 2021;187(2):397-405

Link1

Link2 Link3

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.